Condition: Recurrent Glioblastoma IDH Wildtype · Sponsor: Darell Bigner
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), followed by subcutaneous cervical perilymphatic injections (CPLIs) of 2141-V11 2 and 4 weeks post infusion, then every 3 weeks for a year, and every 4-6 weeks thereafter if patients benefit from therapy.
This description comes directly from the study's public registry record.
Annick Desjardins, MD · 919-684-5301 · dukebrain1@dm.duke.edu
Stevie Threatt · 919-684-5301 · dukebrain1@dm.duke.edu
Always discuss trial participation with your own doctor first.
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06455605